US EditionVenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
- VentureMed Group presented study data at the Charing Cross Symposium in London on April 23, 2025.
- The presentation detailed six-month outcomes from the FLEX FIRST AV Registry in hemodialysis patients with vascular access dysfunction.
- This multi-center observational registry included 130 patients with arteriovenous fistulas or grafts requiring treatment.
- Results showed 100% technical success and 70.7% overall primary patency at six months with zero serious adverse events initially.
- The data demonstrated procedural safety and meaningful durability for this vessel preparation method in challenging clinical cases.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
1
Center
5
Right
Denton Record-Chronicle+18 Reposted by 18 other sources
FLEX Vessel Prep™ System FLEX FIRST AV Registry 6-Month Data and the Hamburg Vessel Prep Experience Prior to Angioplasty presented at Charing Cross Symposium
MINNEAPOLIS, April 23, 2025 /PRNewswire/ -- VentureMed Group, Inc., a privately held leader in medical device innovations for arteriovenous (AV) access and peripheral arterial disease (PAD), announced data presented at the Charing Cross Symposium, April 23 – 25th, London, England.…
·Denton, United States
Read Full Article
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
IRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that the VenoValve® will be featured…
Coverage Details
Total News Sources20
Leaning Left1Leaning Right0Center5Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
